1 / 37

Nursing 210 Fluid and Cells

Nursing management of patients with hematologic dysfunction. Nursing 210 Fluid and Cells. Laurie Brown RN, MSN, MPA-HA, CCRN. Development of Blood Cells. Hemoglobin and Hematacrit. Hb: Women: 12-16 Men: 13.5-18. Hct: Women: 38-47% Men: 40-54%. Complete Blood Count.

sigourney
Download Presentation

Nursing 210 Fluid and Cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nursing management of patients with hematologic dysfunction Nursing 210 Fluid and Cells Laurie Brown RN, MSN, MPA-HA, CCRN

  2. Development of Blood Cells

  3. Hemoglobin and Hematacrit Hb: Women: 12-16 Men: 13.5-18 Hct: Women: 38-47% Men: 40-54%

  4. Complete Blood Count White Blood Cells (WBC) 5,000-10,000

  5. Neutrophil Eosinophil Basophil Lymphocyte Monocyte 50-70% 2-5% 0-2% 20-40% 4-8% WBCDifferential

  6. CBC Platelet Count 150,000-400,000

  7. Red Cells • Mean Corpuscular Hemoglobin (MCH) • Mean Corpuscular Volume (MCV) • Mean Corpuscular Hemoglobin Concentration (MCHC)

  8. Clotting • Extrinsic • Intrinsic

  9. Heparin PTT Coumadin PT or INR Vitamin K Protamine sulfate

  10. Drugs Impairing the Hematologic System • Drugs causing bone marrow suppression • Drugs causing hemolysis • Drugs that disrupt platelet action • Drugs that disrupt clotting action

  11. ANEMIAS • “Can Not Make” • “Lost” • “Destroyed”

  12. Iron Deficiency Pernicious Anemia Folic Acid Deficiency Trauma Chronic loss Sickle Cell Infectious Agents Antibodies Aplastic Anemia G6PD Deficiency ANEMIAS

  13. Sickle Cell Anemia • Pain Control • Sickle cell crisis • Rational for orders • Nursing orders

  14. Pernicious Anemia • Vitamin B 12 • Intrinsic Factor • Cells mutate and become large • Development of Neurological problems

  15. Clotting Problems • Thrombocytopenia • Hemophilia • Von Willebrand • Disseminated Intravascular Coagulation (DIC)

  16. DIC “Imbalance between the process of coagulation and anticoagulation”

  17. Treatment

  18. Heparin Administration • Heparin loading dose • Initial Maintenance Infusion • Dosage calculation often by patients weight

  19. Identification Lab values Drs order verify Pt assessment IV site assessment Documentation Verify with 2nd RN Monitor VS Remain with the patient TransfusionAdministration

  20. Automatic IV infuser pump • Flow rate calculation • Blood/Blood product w/tag • 150 cc NS • Blood Administration Set • Gloves

  21. Blood Bank • Patient name and I.D. number • Unit number and ABO/Rh type on bag with blood bag compatibility tag & bag unit/type • Verify expiration date on blood bag

  22. Autologous Blood Transfusions • Preoperative autologous blood donation • Acute normovolemic hemodilution • Intraoperative autologous transfusion • Postoperative blood salvage

  23. Characteristics of Normal Cells • Limited Cell Division • Specific Morphology • Small Nuclear-Cytoplasmic Ratio • Perform Specific Differentiated Functions • Adhere tightly together… • Are nonmigratory • Grow in an orderly and well differentiated manner • Are contact inhibited

  24. Characteristics of Malignant Cells • Demonstrate rapid or continuous cellular division. • Show anaplastic morphology • Have alargenuclear-cytoplasmic ratio • Lose some or all differentiated functions • Adhere loosely together • Are able to migrate • Grow by invasion • Are not contact-inhibited

  25. Leukemia • AML - Acute Myelogenous • ALL - Acute Lymphocytic • CML - Chronic Myelogenous • CLL - Chronic Lymphocytic

  26. FAB Leukemia Classification • French American British Classification • Historically distinguishing AML from ALL was a major clinical problem • Chemotherapy dependent on tissue type

  27. Acute Leukemia NCCN Guidelines • National Comprehensive Cancer Network (NCCN) has issued guidelines for treatment of many cancers including Leukemia as well as other hematological malignancies http://www.nccn.org/index.html

  28. Bone Marrow Aspiration • Bone marrow biopsy • Bone marrow aspiration

  29. Lymphoma • Hodgkin’s lymphoma • Non-Hodgkin’s lymphoma

  30. Multiple Myeloma • Gammopathy • “M” Protein • called a tumor marker

  31. History of Myeloma • Skeletal evidence of myeloma obtained from Egyptian mummies • First case described in 1844 • 1845 Dr Henry Bence Jones detected heat properties of urinary light chains • 1929 Bone marrow aspiration • 1937 serum protein electrophoresis • 1960 Alkeran and prednisone- first treatment

  32. What is Multiple Myeloma? • A cancer of the bone marrow • The location where cells are produced • The affected cells are plasma cells • Plasma cells produce antibodies (proteins that fight off infection)

  33. To Many Harmful Plasma Cells • Abnormal Plasma Cells are called Myeloma Cells and develop without warning • Myeloma cells collect in bones and cause “soft spots” where the cell is damaged

  34. Normal cells are not being produced in the bone marrow Bones are damaged Bone demineralization (soft spots) Effects of the blood

  35. Symptomatic Multiple Myeloma • Calcium • Renal • Anemia • Bone

More Related